Targeting Matrix Metalloproteinases for Diabetic Retinopathy: The Way Ahead?
-
Published:2019-02-15
Issue:4
Volume:20
Page:324-333
-
ISSN:1389-2037
-
Container-title:Current Protein & Peptide Science
-
language:en
-
Short-container-title:CPPS
Author:
Solanki Ankita1, Bhatt Lokesh K.1, Johnston Thomas P.2, Prabhavalkar Kedar S.1
Affiliation:
1. Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India 2. Division of Pharmaceutical Sciences, University of Missouri-Kansas City, Kansas City, MO, United States
Abstract
Diabetic retinopathy (DR) is a severe sight-threatening complication of diabetes. It causes
progressive damage to the retina and is the most common cause of vision impairment and blindness
among diabetic patients. DR develops as a result of various changes in the ocular environment. Such
changes include accelerated mitochondrial dysfunction, apoptosis, reactive oxygen species production,
and formation of acellular capillaries. Matrix metalloproteinases (MMPs) are one of the major culprits in
causing DR. Under physiological conditions, MMPs cause remodeling of the extracellular matrix in the
retina, while under pathological conditions, they induce retinal cell apoptosis. This review focuses on
the roles of various MMPs, primarily MMP-2 and MMP-9 in DR and also their participation in oxidative
stress, mitochondrial dysfunction, and apoptosis, along with their involvement in various signaling
pathways. This review also underscores different strategies to inhibit MMPs, thus suggesting that MMPs
may represent a putative therapeutic target in the treatment of DR.
Publisher
Bentham Science Publishers Ltd.
Subject
Cell Biology,Molecular Biology,Biochemistry,General Medicine
Reference100 articles.
1. Das A. Invest Ophthalmol Vis Sci, Diabetic Retinopathy: Battling the global epidemic.,, 2016, 57,, 6669-6682, 2. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, Wykoff CC, Gardner TW. Diabetes Care, Diabetic retinopathy: A position statement by the American Diabetes Association.,, 2017, 40,, 412-418, 3. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O’Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY. Diabetes Care, Global prevalence and major risk factors of diabetic retinopathy.,, 2012, 35,, 556-564, 4. Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, Ghaznavi H, Naseripour M. Life Sci, Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; Involvement of autophagy, Inflammation and oxidative stress.,, 2018, 193,, 20-33, 5. Duh EJ, Sun JK, Stitt AW. JCI Insight, Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies.,, 2017, 2,, 1-13,
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|